Harbor Capital Advisors Inc. Purchases New Shares in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Harbor Capital Advisors Inc. bought a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 97,543 shares of the company's stock, valued at approximately $2,438,000. Harbor Capital Advisors Inc. owned about 0.14% of Kiniksa Pharmaceuticals as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Rice Hall James & Associates LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 8.2% in the 3rd quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company's stock worth $16,234,000 after purchasing an additional 49,000 shares in the last quarter. AMI Asset Management Corp purchased a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at approximately $1,281,000. China Universal Asset Management Co. Ltd. raised its position in Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company's stock valued at $195,000 after buying an additional 3,076 shares during the last quarter. Semanteon Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals in the third quarter valued at about $551,000. Finally, Hennion & Walsh Asset Management Inc. grew its position in Kiniksa Pharmaceuticals by 7.6% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 195,852 shares of the company's stock worth $4,894,000 after purchasing an additional 13,886 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Eben Tessari sold 17,500 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total transaction of $470,925.00. Following the sale, the chief operating officer now directly owns 119,911 shares in the company, valued at $3,226,805.01. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the sale, the insider now directly owns 52,038 shares in the company, valued at approximately $1,359,232.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 17,500 shares of the company's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the sale, the chief operating officer now owns 119,911 shares of the company's stock, valued at approximately $3,226,805.01. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 112,692 shares of company stock valued at $2,950,315. Corporate insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ KNSA traded up $0.55 during midday trading on Tuesday, reaching $22.03. The company had a trading volume of 373,477 shares, compared to its average volume of 412,518. The firm's fifty day moving average price is $25.28 and its 200-day moving average price is $22.57. Kiniksa Pharmaceuticals, Ltd. has a one year low of $14.12 and a one year high of $28.15. The stock has a market cap of $1.57 billion, a PE ratio of -156.85 and a beta of 0.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to the consensus estimate of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business's revenue was up 67.4% on a year-over-year basis. During the same period last year, the company posted ($0.20) earnings per share. As a group, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.47 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research report on Tuesday. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 target price for the company. Wedbush raised their price target on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an "outperform" rating in a report on Tuesday, July 23rd. Finally, Evercore ISI raised their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.